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Summary
Background Asthma treatment guidelines recommend increasing corticosteroid dose to control symptoms and reduce 
exacerbations. This approach is potentially flawed because symptomatic asthma can occur without corticosteroid 
responsive type-2 (T2)-driven eosinophilic inflammation, and inappropriately high-dose corticosteroid treatment 
might have little therapeutic benefit with increased risk of side-effects. We compared a biomarker strategy to adjust 
corticosteroid dose using a composite score of T2 biomarkers (fractional exhaled nitric oxide [FENO], blood 
eosinophils, and serum periostin) with a standardised symptom–risk-based algorithm (control).
Methods We did a single-blind, parallel group, randomised controlled trial in adults (18–80 years of age) with severe 
asthma (at treatment steps 4 and 5 of the Global Initiative for Asthma) and FENO of less than 45 parts per billion at 
12 specialist severe asthma centres across England, Scotland, and Northern Ireland. Patients were randomly 
assigned (4:1) to either the biomarker strategy group or the control group by an online electronic case-report form, in 
blocks of ten, stratified by asthma control and use of rescue systemic steroids in the previous year. Patients were 
masked to study group allocation throughout the entirety of the study. Patients attended clinic every 8 weeks, with 
treatment adjustment following automated treatment-group-specific algorithms: those in the biomarker strategy 
group received a default advisory to maintain treatment and those in the control group had their treatment adjusted 
according to the steps indicated by the trial algorithm. The primary outcome was the proportion of patients with 
corticosteroid dose reduction at week 48, in the intention-to-treat (ITT) population. Secondary outcomes were inhaled 
corticosteroid (ICS) dose at the end of the study; cumulative dose of ICS during the study; proportion of patients on 
maintenance oral corticosteroids (OCS) at study end; rate of protocol-defined severe exacerbations per patient year; 
time to first severe exacerbation; number of hospital admissions for asthma; changes in lung function, Asthma 
Control Questionnaire-7 score, Asthma Quality of Life Questionnaire score, and T2 biomarkers from baseline to 
week 48; and whether patients declined to progress to OCS. A secondary aim of our study was to establish the 
proportion of patients with severe asthma in whom T2 biomarkers remained low when corticosteroid therapy was 
decreased to a minimum ICS dose. This study is registered with ClinicalTrials.gov, NCT02717689 and has been 
completed.
Findings Patients were recruited from Jan 8, 2016, to July 12, 2018. Of 549 patients assessed, 301 patients were included 
in the ITT population and were randomly assigned to the biomarker strategy group (n=240) or to the control group 
(n=61). 28·4% of patients in the biomarker strategy group were on a lower corticosteroid dose at week 48 compared 
with 18·5% of patients in the control group (adjusted odds ratio [aOR] 1·71 [95% CI 0·80–3·63]; p=0·17). In the 
per-protocol (PP) population (n=121), a significantly greater proportion of patients were on a lower corticosteroid dose 
at week 48 in the biomarker strategy group (30·7% of patients) compared with the control group (5·0% of patients; 
aOR 11·48 [95% CI 1·35–97·83]; p=0·026). Patient choice to not follow treatment advice was the principle reason for 
loss to PP analysis. There was no difference in secondary outcomes between study groups and no loss of asthma 
control among patients in the biomarker strategy group who reduced their corticosteroid dose.
Interpretation Biomarker-based corticosteroid adjustment did not result in a greater proportion of patients reducing 
corticosteroid dose versus control. Understanding the reasons for patients not following treatment advice in both 
treatment strategies is an important area for future research. The prevalence of T2 biomarker-low severe asthma was low.
Funding This study was funded, in part, by the Medical Research Council UK.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
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Introduction
Treatment guidelines for asthma recommend a step-wise 
increase in inhaled corticosteroid (ICS) treatment to 
control symptoms and reduce exacerbations.1 However, 
as many as 50% of patients with symptomatic asthma 
might not have eosinophilic airways inflammation and 
respond poorly to corticosteroids.2–4 In this population, 
there is a clear potential for treatment to be increased to 
high intensity ICS and oral corticosteroids (OCS) without 
therapeutic benefit and with an increased potential for 
side-effects.5–9
Titrating corticosteroids with the goal of minimising 
sputum eosinophilia reduces severe exacerbations and 
allows safe down-titration of corticosteroid treatment 
in severe asthma.10–12 However, sputum-guided manage-
ment is difficult to deliver in a real-world setting. When 
used as a single biomarker of type-2 (T2) cytokine 
inflammation, fractional exhaled nitric oxide (FENO)-
guided management in mild and moderate asthma 
results in reduced exacerbations with minimal effect on 
lung function or asthma symptoms.12 However, whether 
a biomarker-based strategy can be used to primarily 
reduce corticosteroid exposure in patients with severe 
asthma on high-dose treatment is unclear. Asthma 
guidelines advo cate corticosteroid reduction by assess-
ment of exacerbation risk and symptom control but 
there is little evidence base to support this strategy in 
patients with severe asthma on high-dose corticosteroid 
treatment, particularly in patients receiving OCS.1 Given 
that high doses of corticosteroid cause considerable 
morbidity, new algorithms that can be delivered in the 
clinic for guiding corticosteroid treatment in patients 
with severe asthma are needed.
We have shown previously that a raised composite 
score of three T2-inflammation biomarkers (FENO, 
blood eosinophils, and serum periostin) is independently 
associated with increased risk of exacerbation in patients 
with severe asthma.13 This suggests that a low composite 
score could be used to identify a low-risk population 
in whom corticosteroid dose could be safely reduced.13 
In this randomised, multicentre, parallel group trial in 
patients with severe asthma, we aimed to show whether 
such a scoring system could be used to guide 
corticosteroid treatment better than a standardised 
symptom-based or risk-based strategy, and would do so 
more effectively without increasing exacerbation rates, 
worsening asthma control, or precipitating a fall in lung 
function. An important secondary aim of our study was 
to establish the proportion of patients with severe asthma 
in whom T2 biomarkers remain low when corticosteroid 
therapy is decreased to a minimum ICS dose.
Methods
Study design and participants
This was a multicentre, single-blind (study participant), 
parallel group randomised controlled trial in patients 
with severe asthma. Details of the protocol have been 
published elsewhere.14 In brief, we compared a composite 
biomarker-based adjustment of corticosteroid therapy 
(using a composite index of blood eosinophil count, 
serum periostin, and FENO concentration; active 
intervention) with adjustments using an algorithm 
Research in context
Evidence before this study
Treatment guidelines for asthma recommend a step-wise 
increase of corticosteroid treatment to control symptoms and 
reduce exacerbations. Evidence suggests minimal therapeutic 
benefit from corticosteroids in the absence of type 2 (T2)-driven 
eosinophilic inflammation, and in many symptomatic patients 
with asthma treated with corticosteroids, this type of 
inflammation is not present. Biomarker-based adjustment of 
corticosteroid treatment in severe asthma by means of sputum 
eosinophilia reduces exacerbations and allows safe down-
titration of corticosteroid treatment, but is difficult to deliver in 
real-world settings. To our knowledge, no previous study has 
considered a biomarker-based strategy with the primary aim to 
reduce corticosteroid treatment in patients with severe asthma 
on high-dose treatment. Guidelines advocate corticosteroid 
dose reduction based on a combination of exacerbation risk and 
symptom control but evidence to support use of this strategy in 
severe asthma is scarce.
Added value of this study
We found no significant difference in the proportion of 
patients who had reduced corticosteroid dose at week 48 
between those who were assigned to the T2 biomarker 
strategy compared with those assigned to standard care. 
A high proportion of patients chose not to follow study 
treatment advice but in those who did, a significant benefit 
was seen in patients in the biomarker-based strategy group. 
Importantly, patients who reduced treatment according to 
biomarker-directed therapy showed no evidence of clinical 
deterioration, despite being on lower corticosteroid doses.
Implications of all the available evidence
Factors driving patient choice not to follow advice to reduce 
corticosteroid treatment are an important area for future 
research. We suggest that before progression to high-dose 
corticosteroid treatment, predictive biomarkers of therapeutic 
response should be assessed to guide treatment decisions, 
because once a patient becomes established on high-dose 
corticosteroid treatment, biomarker-driven corticosteroid 
reduction can be difficult to achieve in symptomatic patients.
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based on asthma symptoms, lung function, and recent 
exacerbation history (control). The Medical Research 
Council Refractory Asthma Stratification Programme 
research consortium included a patient input platform 
recruited to provide direction with regard to patient 
needs and understanding; the group was recruited 
through Asthma UK.
The study was done in patients with severe asthma 
(Global Initiative for Asthma steps 4 and 5 classification 
of asthma severity) attending one of 12 specialist severe 
asthma centres across the UK (appendix pp 2–3). Patients 
eligible for enrolment were aged 18–80 years, had met 
well characterised diagnostic criteria for severe asthma, 
and had an FENO of less than 45 parts per billion (ppb) 
to enrich for a T2 biomarker-low population with 
greater opportunity to reduce corticosteroid treatment 
(appendix pp 5–6). Full eligibility criteria are included in 
the trial protocol (appendix pp 5–6).
The protocol was reviewed and approved by the Office 
for Research Ethics Northern Ireland (NI0158) and 
obtained local National Health Service Research and 
Development approval for individual sites. All patients 
provided written informed consent for study participation.
Randomisation and masking
Following a 2-week run-in period, patients were randomly 
assigned in a 4:1 ratio to one of the two treatment groups: 
biomarker-based adjustment strategy or control adjust-
ment strategy. This randomisation ratio was employed 
to assist study recruitment to the biomarker-guided 
treatment strategy and to ensure maximal numbers 
of patients undergoing biomarker-based corticosteroid 
treatment adjustment (to establish the proportion of 
patients who remained T2 biomarker-low when cortico-
steroid doses were reduced). The online electronic 
case-report form (Dendrite Clinical Systems, Reading, 
UK) assigned patients following a random schedule 
to one of the treatment groups in blocks of ten, stratified 
by asthma control (Asthma Control Question naire 
[ACQ-7] ≥1·5) and use of rescue systemic steroids 
(≥2 courses in previous year). This was a single-blind 
study with patients masked to their allocated treatment 
group throughout the study.
Procedures
Following randomisation, patients attended the clinic 
every 8 weeks for review of their asthma control and 
treatment. Patient ACQ-7 scores, post-bronchodilator 
FEV1, and FENO concentration data were entered into 
the electronic case-report form at all study visits; blood 
eosinophil count data were entered into the electronic 
case-report form within 24 h of the visit; and periostin 
values were entered automatically by a central laboratory 
within 3–5 days of sample collection (or when available). 
The electronic case-report form software processed 
individual patient data by means of the study algorithms 
(tables 1 and 2) and generated a treatment advisory 
in both treatment groups (ie, recommendations for 
therapeutic adjustment as appropriate to decrease, 
maintain, or increase treatment; appendix, pp 6–8).
Patients in both groups received instructions at each 
clinic visit from dedicated study coordinators trained in 
the study procedures and working closely with study 
investigators; those in the biomarker strategy group 
received a default advisory to maintain treatment and 
those in the control group had their treatment adjusted 
according to the steps indicated by the trial algorithm. 
All participants were contacted once biomarker results 
were available, thereby ensuring patients remained 
masked to which treatment group they were in; patients 
in the control group received a default advisory to 
maintain their treatment, whereas treatment advice in 
the biomarker group was based on the result generated 
by the trial algorithm. A default advisory to maintain 
treatment was provided if, for practical reasons, any 
individual biomarker measure was not available. When 
patients reported an asthma exacerbation, it was 
managed according to the patient’s self-management 
plan with no adjustment in background treatment. 
Planned therapy adjustments were deferred until the 
next scheduled study visit. Patients remained in the 
study irrespective of whether or not they followed their 
treatment advisories. Patients were seen by the clinical 
investigator in the clinic if there was any concern 
0 1 2
FENO, ppb <15 15–30 >30
Blood eosinophil count, n/µL <150 150–300 >300
Periostin, ng/mL <45 45–55 >55
FENO, blood eosinophil count, and serum periostin were measured at each study 
visit with each biomarker assigned a score of 0, 1, or 2. The composite biomarker 
score was calculated automatically by the eCRF software using the rounded 
average of the sum of all three biomarker scores. Treatment algorithms were 
generated automatically by the eCRF software; a composite biomarker score of 0 
advised treatment reduction, a score of 1 advised maintenance of current 
treatment, and a score of 2 advised treatment increase. ppb=parts per billion. 
FENO=fractional exhaled nitric oxide. eCRF= electronic case-report form.
Table 1: Composite biomarker scoring system 
Score
ACQ-7 ≥1·5 and ≥1 change from baseline score or a severe exacerbation since last study visit 
(previous 8 weeks at baseline randomisation visit)
2
ACQ-7 is 1·0 to <1·5 or ACQ-7 ≥1·5 and <1 change from baseline score AND no severe 
exacerbation since last study visit (previous 8 weeks at baseline randomisation visit)
1
ACQ-7 <1·0 and no severe exacerbation since last study visit (previous 8 weeks at baseline 
randomisation visit)
0
ACQ-7 and recent exacerbation history were recorded at each study visit. To mirror usual clinical care, patients were not 
asked to withhold bronchodilator medication before study spirometry measurements. Treatment algorithms were 
generated automatically by the eCRF software;  this was considered essential as prestudy observations in the UK Severe 
Asthma Registry had identified standard care and specifically corticosteroid treatment regimes differed substantially 
across clinical centres. A score of 0 advised treatment reduction, a score of 1 advised maintenance of current treatment 
and a score of 2 advised treatment increase. ACQ-7=Asthma Control Questionnaire-7. eCRF= electronic case-report form.
Table 2: Symptom–risk-based treatment adjustment
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about persistent poorly controlled asthma or treatment 
adjustments.
On completion of the study at week 48, all patients 
underwent final assessment. In addition to standard 
sample collection, patients were asked to identify 
which treatment strategy they thought they had been 
assigned to.
Outcomes
The primary outcome was the proportion of patients with 
a reduction in ICS or OCS dose from baseline to week 48. 
Secondary outcomes were the ICS dose at the end of the 
study, cumulative dose of ICS during the study, and 
proportion of patients on maintenance OCS at study end. 
Asthma outcomes were the rate of protocol-defined 
severe exacerbations per patient year, time to first severe 
exacerbation, number of hospital admissions for asthma, 
changes in lung function, ACQ-7 score, Asthma Quality 
of Life Questionnaire (AQLQ) score, and T2 biomarkers 
from baseline to week 48. We expected that some patients 
would be reluctant to progress to OCS irrespective of 
their biomarker or symptom score status, so this 
reluctance was a prespecified secondary outcome. To 
facilitate the analysis, detailed information was collected 
on whether treatment advisories were followed at each 
study visit with reasons for non-compliance recorded 
where possible. A severe asthma exacerbation was 
recorded as new or as increased asthma symptoms if it 
led to at least one of the following: a doubling of 
daily OCS dose (for patients on maintenance OCS); 
the prescription of a course of rescue OCS for 3 or 
more consecutive days; administration of intravenous or 
intramuscular corticosteroid for asthma; or hospital visit 
for asthma. Patients were asked to manage exacerbations 
according to their written personalised self-management 
plans that were provided as part of their routine clinical 
care. We did a post-hoc analysis to explore the effects of 
biomarker-based management in patients with 
uncontrolled asthma.
Statistical analysis
It was assumed that a 20% difference between the study 
groups in the proportion of patients receiving a lower 
dose of corticosteroid treatment would be clinically 
meaningful. This assumption was supported by the 
findings of a subsequent Delphi exercise of international 
severe asthma experts.15 Assuming a study dropout rate 
of approximately 20% and a 10% reduction in the number 
of patients achieving a lower dose of corticosteroid in the 
control group, we estimated that 300 patients, randomly 
assigned in a 4:1 ratio, would provide the study with 
80% power to show a 20% difference in corticosteroid 
reduction between the treatment groups.
Analysis was done according to a prespecified 
statistical analysis plan under the intention-to-treat (ITT) 
principle; two-tailed hypothesis tests were done at the 
5% α-level with 95% CIs used throughout. For the 
primary outcome, reductions in corticosteroid doses 
between the start and end of the study were analysed by 
means of logistic regression models, adjusted for age, 
sex, smoking status, treatment centre, use of rescue 
steroids in the year before randomisation (categorised as 
<2 and ≥2 courses) and ACQ-7 score (categorised as <1·5 
and ≥1·5) at baseline. Multiple imputation with chained 
equations was used, which assumed that data were 
missing at random with imputation models including 
treatment group, age, sex, smoking status, treatment 
centre, rescue steroids in the year before randomisation 
(categorised as <2 and ≥2 courses), ACQ-7 score 
(categorised as <1·5 and ≥1·5) at baseline, and change in 
corticosteroid dose between baseline and the first visit.16
All patients who attended at least one follow-up 
visit were included in the primary outcome analysis. 
Secondary outcomes were analysed by means of 
regression. Linear models were used for ACQ-7, AQLQ, 
FEV1, log (FENO), log [blood eosinophils], periostin, ICS 
dose, and OCS dose. Negative binomial models were used 
for protocol-defined exacerbation and hospitalisation 
counts. Logistic models were used for the probability of 
refusing to start OCS, and Cox proportional hazards 
models were used for the time to first protocol-defined 
exacerbation. All models were adjusted for age, sex, 
smoking status, treatment centre, rescue steroid use in 
Figure 1: Trial profile
FENO=fractional exhaled nitric oxide. PV=protocol violation. FVC=forced vital capacity.
248 excluded
105 FENO too high
43 no documented reversibility
26 recent exacerbation
14 other health issues
13 unable to comply with study procedures
13 smoker
11 unknown
9 PV at entry
8 inhaled steroid dose too low
3 steroid dosing not stable
2 FEV1/FVC ratio >70%
1 failed methacholine challenge
61 allocated to symptom-based strategy (control 
 group)
549 patients assessed for eligibility
301 randomly assigned
240 allocated to biomarker strategy group
59 analysed
2 did not attend any follow-up visit
236 analysed 
4 did not attend any follow-up visit
7 withdrawals
5 lost to follow-up
1 lack of compliance
1 unclear
31 withdrawals
26 lost to follow-up
5 protocol violation
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the year before randomisation (categorised as <2 and 
≥2 courses), and ACQ-7 score at baseline (categorised as 
<1·5 and ≥1·5). Data for outcomes measured at each study 
visit (ACQ-7, AQLQ, FEV1, FENO, blood eosinophil count, 
periostin, ICS dose, and OCS dose) were further adjusted 
for the baseline measurement of the outcome. Secondary 
analysis was only done on data from patients who 






Age at inclusion, years 55·2 (13·4) 57·5 (11·9)
Sex
Female 151 (63%) 43 (70%)
Male 89 (37%) 18 (30%)
Ethnicity*
Caucasian 221 (92%) 58 (95%)
Non-Caucasian 19 (8%) 3 (5%)
Body-mass index, kg/m2 31·4 (7·2) 32·5 (7·2)
Smoking status
Never smoked 183 (76%) 41 (67%)
Ex-smoker 57 (24%) 20 (33%)
Working status
Not working owing to asthma-
related ill health
39 (16%) 13 (21%)
Not working owing to other 
cause
76 (32%) 26 (43%)
Working part-time owing to 
asthma-related ill health
12 (5%) 1 (2%)
Working part-time owing to 
other cause
38 (16%) 1 (2%)
Student 2 (1%) 0
Full time 72 (30%) 20 (33%)
Atopic disease 167 (70%) 40 (66%)
Hospital admissions for asthma in 
last year
0·0 (0·0–0·0) 0·0 (0·0–0·0)
Accident and emergency 
department visits in last year
0·0 (0·0–0·0) 0·0 (0·0–0·0)
General practitioner visits for 
asthma in last year
1·0 (0·0–3·0) 1·0 (0·0–3·0)
Rescue courses of oral 
corticosteroids in past year
2·0 (1·0–4·0) 2·0 (1·0–4·0)
Previous admission for asthma to 
intensive therapy unit
55 (22·9%) 9 (14·8%)
Number of previous admissions 
for asthma to intensive therapy 
unit
1·0 (1·0–2·0) 1·0 (1·0–2·0)
Ever been ventilated 27 (11%) 4 (7%)
Rhinitis 168 (70%) 40 (66%)
Eczema 85 (35%) 15 (25%)
Nasal polyps 58 (24%) 15 (25%)
Previous nasal surgery 57 (24%) 13 (21%)
Oesophageal reflux 137 (57%) 42 (69%)
Aspirin sensitivity 33 (14%) 14 (23%)
Depression or anxiety 73 (30%) 19 (31%)
Hypertension 70 (29%) 24 (39%)
Osteoporosis or osteopenia 57 (24%) 9 (15%)
Osteoarthritis 64 (27%) 14 (23%)
Hypercholesterolaemia 39 (16%) 14 (23%)
Diabetes 28 (12%) 6 (10%)
Cataracts 26 (11%) 7 (11%)
Obstructive sleep apnoea 15 (6%) 2 (3%)
Ischaemic heart disease 8 (3%) 4 (7%)
Peptic ulcer 8 (3%) 0






(Continued from previous column)
Stroke 4 (2%) 2 (3%)
Chronic kidney disease 4 (2%) 3 (5%)
Glaucoma 4 (2%) 0
Myocardial infarction 2 (1%) 1 (2%)
FEV1 2·2 (0·7) 2·1 (0·7)
% predicted FEV1 75·3% (19·2) 76·5% (19·8)
Forced vital capacity 3·3 (0·9) 3·2 (0·9)
% predicted forced vital capacity 90·6% (16·3) 93·1% (18·9)
FEV1/forced vital capacity 0·66 (0·11) 0·65 (0·13)
PEF 380·4 (126·4) 359·6 (133·2)
















FENO, ppb 21 (13–29) 19 (12–28)






Periostin, ng/mL 52·8 (15·7) 53·5 (18·2)
Composite biomarker score
0 55 (23%) 13 (21%)
1 135 (56%) 37 (61%)
2 48 (20%) 10 (16%)
Maintenance oral corticosteroids 
user
87 (36%) 24 (39%)
Oral corticosteroid dose (mg) 10 (5–10) 9 (5–10)
Inhaled oral corticosteroids dose 






LAMA user 109 (45%) 35 (57%)
Patient reported outcomes
Asthma Control Questionnaire-7 
score
2·0 (1·1) 2·0 (1·3)
Asthma Quality of Life 
Questionnaire total score
4·9 (1·3) 4·7 (1·6)
Data are n (%), median (IQR), or mean (SD). LAMA=long-acting muscarinic 
antagonist. FENO=fractional exhaled nitric oxide. PEF=peak exploratory flow rate. 
ppb=parts per billion. *Ethnicity as per Global Lung Initiative 2012. †Sputum data 
was available in 123 subjects at baseline.
Table 3: Demographics, medical history, lung function, biomarkers, 
corticosteroid treatment, and patient reported outcomes in the 
randomised population
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The prespecified per-protocol (PP) analysis excluded 
data from patients who did not attend a study visit or who 
did not follow any study treatment advisory (except in 
instances where patients had low cortisol or if patients 
were already on the lowest ICS dose allowed according to 
the protocol). The PP analysis adjusted for the same set 
of variables as the primary analyses. Exploratory post-hoc 
analyses were done to understand the observed difference 
between the results seen in the ITT population versus 
the PP population: analysis restricted to patients who had 
uncontrolled asthma at study entry (defined as an 
ACQ-7 ≥1·5) and exacerbation rate in patients not 
following treatment advisories compared with those 
following treatment advisories. We assessed the effect of 
the imputation on our primary outcome by repeating 
our analysis under a complete-case framework. 
Additionally, we assessed the robustness of our findings 
to missing-not-at-random mechanisms by assuming 
a best-case scenario (assuming all withdrawals would 
have reduced their corticosteroid dose) and worst-case 
scenario (assuming all withdrawals would not have 
reduced their corticosteroid dose). All analyses were 
done with the STATA 16 software package (StataCorp, 
TX, USA). Conduct of the trial was monitored by an 
independent trial steering committee. This study is 
registered with ClinicalTrials.gov, NCT02717689.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. All authors had full access to all the data in the 
study and had final responsibility for the decision to 
submit for publication.
Results
Patients were recruited from Jan 8, 2016, to July 12, 2018 
(figure 1). Of 549 patients assessed, 301 were randomly 
assigned to the biomarker strategy group (n=240) or to 
the control group (n=61). Baseline demographics, 
medical history, comorbidities, lung function, and 
corticosteroid treatment at baseline are shown in 
table 3.
For the primary outcome in the ITT population, 28·4% 
of patients in the biomarker strategy group reduced their 
dose of corticosteroid at 48 weeks compared with 18·5% 
of patients in the control group (adjusted odds ratio 
[aOR] 1·71 [95% CI 0·80–3·63]; p=0·17; figure 2A; 
table 4). Our estimates were similar when doing a 
complete-case analysis (aOR 1·70 [0·79–3·67]), and were 
robust to missing-not-at-random assumptions under 
both the best-case scenario (aOR 1·74 [0·81–3·74]) and 
worst-case scenario (aOR 1·69 [0·78–3·65]). There was 
no significant difference in secondary outcomes between 
study groups in the ITT analysis (table 4) and no 
difference in lung function, symptom scores, quality of 
life, or biomarkers in patients who reduced their 
corticosteroid dose (appendix p 9).
In the prespecified PP analysis of 121 patients, a 
significantly greater proportion of patients were on a 
lower dose of corticosteroid at week 48 in the biomarker 
study group (30·7% of patients) compared with the 
control group (5·0% of patients; aOR 11·48 [95% CI 
1·35–97·83]; p=0·026; figure 2B; table 4). The baseline 
characteristics of the PP and ITT populations were 
similar except that in the PP population, patients in the 
control group were more symptomatic compared with 
the biomarker strategy group (mean ACQ-7 score 2·6 
[SD 1·1] vs 2·0 [1·1]; p=0·022) and had greater 
impairment of AQLQ (mean total score 4·2 [SD 1·2] vs 
5·0 [1·2]; p=0·0086; appendix p 11). The estimated 
number of patients needed to treat to achieve one patient 
on lower corticosteroid dose was four (95% CI 3–9). As 
with the ITT analysis, other than FENO, there was no 
significant difference in secondary outcomes (table 4) 
Figure 2: Proportion of patients who reduced corticosteroid treatment dose over 48 weeks
(A) In the intention-to-treat population. (B) In the per-protocol population. (C) In the group with uncontrolled 
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and no worsening of lung function, symptom scores, 
quality of life, or biomarkers in patients who had a 
reduction in corticosteroid dose (appendix p 9).
The PP population was 40% of the ITT population as a 
consequence of patients not following at least one 
treatment advisory (n=124), withdrawing from the study 
Control group Biomarker strategy group Unadjusted analysis Adjusted analysis
n Effect estimate (95% CI) n Effect estimate (95% CI) Odds ratio (95% CI) p value Odds ratio (95% CI) p value
Intention-to-treat analysis
Decrease in corticosteroid 
dose*
54 18·5% (9·3 to 31·4) 208 28·4% (22·3 to 35·0) 1·73 (0·83 to 3·61) 0·14 1·71 (0·80 to 3·63) 0·17
Inhaled corticosteroid dose 
(beclometasone 
dipropionate, µg equivalent)





54 724 763 
(684 245 to 765 281)
209 718 298 
(676 416 to 760 180)
−6465  
(−90 905 to 77 976)
0·88 –4348  
(–87 909 to 79 212)
0·92
Oral corticosteroid dose, mg 54 6 (4 to 8) 208 5 (4 to 6) −1 (−3 to 2) 0·58 –1 (–2 to 1) 0·46
Cumulative oral corticosteroid 
dose, mg
54 1626 (1109 to 2142) 209 1631 (1327 to 1935) 6 (−643 to 654) 0·99 55 (–581 to 691) 0·87
Oral corticosteroid use* 54 55·6% (41·4 to 69·1) 208 49·5% (42·5 to 56·5) 0·78 (0·43 to 1·43) 0·43 0·79(0·36 to 1·74) 0·56
ACQ-7 score 54 2·2 (1·9 to 2·6) 206 2·0 (1·8 to 2·1) −0·3 (−0·6 to 0·1) 0·16 –0·1 (–0·3 to 0·2) 0·47
AQLQ total score 52 4·7 (4·2 to 5·1) 206 5·0 (4·8 to 5·2) 0·4 (−0·1 to 0·8) 0·108 0·2 (–0·2 to 0·5) 0·36
% predicted FEV1 54 72·1 (66·5 to 77·7) 204 73·2 (70·6 to 75·8) 1·1 (−4·7 to 6·8) 0·72 0·4 (–2·7 to 3·6) 0·80
FENO† 54 19·5 (17·5 to 25·0) 205 22·0 (19·0 to 25·0) 1·06 (0·88 to 1·29) 0·53 1·02 (0·87 to 1·19) 0·85
Blood eosinophil count, 
10⁹ cells per L†
51 0·31 (0·26 to 0·39) 206 0·20 (0·18 to 0·23) 0·66 (0·49 to 0·89) 0·0062 0·79 (0·61 to 1·03) 0·078
Periostin, ng/mL 51 54·2 (48·7 to 59·7) 201 51·4 (49·5 to 53·4) −2·8 (−7·5 to 2·0) 0·25 –2·0 (–5·0 to 1·0) 0·19
Annual exacerbation rate‡ 54 1·67 (1·35 to 2·06) 208 1·36 (1·21 to 1·54) 0·82 (0·58 to 1·16) 0·26 0·84 (0·61 to 1·15) 0·28
Time to first exacerbation§ ·· ·· ·· ·· 0·72 (0·50 to 1·05) 0·085 0·77 (0·53 to 1·13) 0·18
Annual hospitalisation rate‡ 54 0·16 (0·08 to 0·32) 208 0·10 (0·06 to 0·15) 0·62 (0·25 to 1·50) 0·29 0·77 (0·32 to 1·84) 0·56
Refused to initiate oral 
corticosteroid*
16 43·8% (19·8 to 70·1) 101 56·4% (46·2 to 66·3) 1·67 (0·58 to 4·82) 0·35 0·80 (0·23 to 2·76) 0·72
Per-protocol analysis
Decrease in corticosteroid 
dose*
20 5·0% (0·1 to 24·9) 101 30·7% (21·9 to 40·7) 8·41 (1·08 to 65·68) 0·042 11·48 (1·35 to 97·83) 0·026
Inhaled corticosteroid dose 
(beclometasone dipropionate 
µg equivalent)





20 706 610 
(650 247 to 762 973)
101 665 711 
(620 861 to 710 561)
−40 899 
(−143 437 to 61 639)
0·43 −52 599 
(−162 431 to 57 234)
0·35
Oral corticosteroid dose, mg 20 7 (3–10) 101 5 (4–7) −1 (−5 to 2) 0·39 −2 (−5 to 0) 0·088
Cumulative oral corticosteroid 
dose, mg
20 1721 (812 to 2629) 101 1644 (1217 to 2071) −77 (−1099 to 945) 0·88 13 (−1070 to 1096) 0·98
Oral corticosteroid use* 20 65·0% (40·8 to 84·6) 101 53·5% (43·3 to 63·5) 0·62 (0·23 to 1·68) 0·35 0·43 (0·10 to 1·78) 0·24
ACQ-7 score 20 2·4 (1·9 to 3·0) 100 1·9 (1·7 to 2·2) −0·5 (−1·0 to 0·0) 0·071 0·1 (−0·3 to 0·5) 0·52
AQLQ total score 18 4·2 (3·5 to 4·9) 99 5·1 (4·8 to 5·4) 0·9 (0·2 to 1·6) 0·010 0·5 (−0·1 to 1·1) 0·11
% predicted FEV1 20 70·2 (59·0 to 81·4) 99 72·2 (68·0 to 76·5) 2·0 (−8·4 to 12·5) 0·71 −0·9 (−6·8 to 5·0) 0·76
FENO† 20 13·5 (9·0 to 25·0) 100 21·0 (19·0 to 24·0) 1·50 (1·14 to 1·97) 0·0037 1·39 (1·07 to 1·80) 0·014
Blood eosinophil count, 
10⁹ cells per L†
19 0·35 (0·26 to 0·47) 100 0·19 (0·16 to 0·21) 0·63 (0·39 to 1·01) 0·053 0·95 (0·62 to 1·47) 0·83
Periostin, ng/mL 19 49·1 (44·5 to 53·7) 97 50·7 (48·2 to 53·1) 1·5 (−4·3 to 7·4) 0·61 −0·8 (−4·9 to 3·3) 0·71
Annual exacerbation rate‡ 20 1·29 (0·86 to 1·92) 101 1·04 (0·86 to 1·27) 0·82 (0·45 to 1·48) 0·50 0·89 (0·49 to 1·61) 0·69
Time to first exacerbation§ ·· ·· ·· ·· 0·86 (0·46 to 1·60) 0·63 0·80 (0·40 to 1·61) 0·54
Annual hospitalisation rate‡ 20 0·11 (0·03 to 0·43) 101 0·12 (0·06 to 0·21) 1·09 (0·23 to 5·13) 0·91 2·15 (0·38 to 12·27) 0·39
Refused to initiate oral 
corticosteroids*
3 0·0% (0·0 to 70·8) ·· 0·0% (0·0 to 18·5) ·· ·· ·· ··
(Table 4 continues on next page)
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(n=32), or missing at least one study visit (n=18). Overall, 
1041 (85%) of 1224 treatment advisories were followed in 
the biomarker-based group and 257 (81%) of 318 in the 
control group, though this was lower in both groups 
when a treatment change was mandated (273 [65%] of 
419 in the biomarker strategy group and 77 [58%] of 
133 in the control group (appendix p 13).
There was a wide variation in the number of deviations 
from the protocol seen at individual clinical centres 
(appendix p 12). The predominant reason for not 
following a treatment advisory was the patient’s choice 
not to do so (appendix p 13) and adherence to treatment 
advice reduced as the study progressed (appendix p 13). 
Patients showed a reluctance to initiate regular OCS 
(56% in the biomarker strategy group and 44% in the 
control group). We also observed a reluctance to reduce 
corticosteroid treatment and notably, in the biomarker 
strategy group, these patients were more symptomatic 
than those who did follow a reduce advisory (ACQ-7 
2·5 [SD 1·2] vs 1·8 [1·0]; p<0·0001). Those who were 
reluctant to reduce corticosteroid treatment also 
had lower lung function (FEV1 72·4% [SD 17·6] vs 
82·8% [19·2]; p=0·0002) with worse airflow obstruction 
(FEV1/forced vital capacity [FVC] 65% [SD 12] vs 70% [12]; 
p=0·0016). There was no difference in the biomarker 
profile of patients who reduced treatment and those who 
did not.
The odds ratio of patients reducing corticosteroid dose 
in the biomarker strategy group remained significant 
when the PP definition was relaxed to include patients 
who were only non-adherent to the study protocol on 
one (n=200; aOR 4·54 [95% CI 1·30–15·87]; p=0·018) or 
two (n=237; aOR 2·64 [1·04–6·72]; p=0·041) study visits 
or treatment advisories.
In the biomarker strategy group, exacerbation rates 
were significantly higher in those patients who did 
not follow treatment advisories compared with those 
who did (adjusted hazard ratio [aHR] 1·64 [95% CI 
1·13–2·38]; p=0·010; figure 3A) but this was not seen in 
the control group (aHR 1·07 [0·64–1·79]; p=0·80; 
figure 3B). This increased exacerbation rate was noted 
in patients who did not reduce treatment as well as 
those who did not increase treatment in the biomarker 
strategy group (appendix p 14). Overall, 60% of those 
patients who completed the study had a protocol-defined 
exacerbation.
Control group Biomarker strategy group Unadjusted analysis Adjusted analysis
n Effect estimate (95% CI) n Effect estimate (95% CI) Odds ratio (95% CI) p value Odds ratio (95% CI) p value
(Continued from previous page)
Uncontrolled asthma (ACQ-7 ≥1·5)
Decrease in corticosteroid 
dose*
35 5·7% (0·7 to 19·2) 125 26·4% (18·9 to 35·0) 5·92 (1·35 to 26·04) 0·019 5·78 (1·27 to 26·23) 0·023
Inhaled corticosteroid dose 
(beclometasone dipropionate 
µg equivalent)





35 746 503 
(701 511 to 791 494)
126 742 762 
(684 624 to 800 901)
−3741 
(−115 557 to 108 076)
0·95 8525  
(−103 243 to 120 292)
0·88
Oral corticosteroid dose, mg 35 7 (4 to 9) 125 6 (5 to 8) −0 (−3 to 3) 0·76 −2 (−4 to 1) 0·15
Cumulative oral corticosteroid 
dose, mg
35 1864 (1159 to 2570) 126 1927 (1487 to 2366) 63 (−838 to 963) 0·89 39 (−890 to 968) 0·93
Oral corticosteroid use* 35 62·9% (44·9 to 78·5) 125 55·2% (46·0 to 64·1) 0·73 (0·34 to 1·57) 0·42 0·49 (0·17 to 1·36) 0·17
ACQ-7 score 35 2·7 (2·3 to 3·1) 123 2·5 (2·3 to 2·7) −0·2 (−0·7 to 0·2) 0·28 0·0 (−0·3 to 0·4) 0·82
AQLQ total score 34 4·0 (3·5 to 4·5) 123 4·4 (4·1 to 4·6) 0·4 (−0·2 to 0·9) 0·17 0·2 (−0·3 to 0·7) 0·42
% predicted FEV1 35 66·2 (59·4 to 72·9) 122 70·5 (67·1 to 73·9) 4·4 (−2·8 to 11·5) 0·24 0·8 (−2·8 to 4·3) 0·68
FeNO† 35 18·0 (12·0 to 25·0) 122 22·0 (21·0 to 26·0) 1·38 (1·10 to 1·73) 0·0057 1·24 (1·02 to 1·51) 0·032
Blood eosinophil count,       
10⁹ cells per L†
33 0·27 (0·22 to 0·36) 123 0·18 (0·16 to 0·20) 0·64 (0·43 to 0·93) 0·019 0·81 (0·57 to 1·14) 0·23
Periostin (ng/mL) 32 50·7 (45·4 to 56·0) 120 50·0 (47·8 to 52·2) −0·7 (−5·6 to 4·2) 0·78 −0·1 (−3·1 to 2·9) 0·96
Annual exacerbation rate‡ 35 1·92 (1·50 to 2·46) 125 1·70 (1·48 to 1·95) 0·88 (0·60 to 1·29) 0·52 0·93 (0·65 to 1·33) 0·69
Time to first exacerbation§ ·· ·· ·· ·· 0·76 (0·49 to 1·16) 0·20 0·83 (0·53 to 1·32) 0·44
Annual hospitalisation rate‡ 35 0·21 (0·10 to 0·45) 125 0·13 (0·08 to 0·21) 0·60 (0·24 to 1·50) 0·27 0·67 (0·26 to 1·71) 0·40
Refused to initiate oral 
corticosteroid*
11 27·3% (6·0 to 61·0) 43 41·9% (27·0 to 57·9) 1·92 (0·45 to 8·26) 0·38 1·18 (0·20 to 6·94) 0·85
Data are mean (95% CI), effect estimate shown as mean difference unless otherwise stated. ACQ-7=Asthma Control Questionnaire 7. AQLQ=Asthma Quality of Life Questionnaire. FENO=fractional exhaled nitric 
oxide. *Data are proportion (95% CI), effect estimate shown as odds ratio. †Data are median (bootstrapped 95% CI), effect estimate shown as ratio of geometric means. ‡Value shown as rate (95% CI), effect 
estimate shown as rate ratio. §Effect estimate shown as hazard ratio. 
Table 4: Effects on corticosteroid treatment dose, lung function, asthma symptoms, asthma related quality of life, and type-2 biomarkers
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Given the greater symptom burden in patients not 
following advice to reduce treatment in the biomarker 
strategy group, we did an exploratory post-hoc analysis 
in those patients with uncontrolled asthma at baseline 
(ACQ-7 ≥1·5). These patients were predominantly 
female, with obesity, not in current employment owing 
to asthma-related ill health, reported clinical depression 
or anxiety, and had more unscheduled asthma care, with 
twice as many on maintenance OCS. They also had 
significantly lower FEV1 and FVC but no difference in 
FEV1/FVC (appendix p 15). Analysis of outcomes in this 
subgroup indicated that a greater proportion of patients 
were taking a lower dose of corticosteroid treatment at 
week 48 in the biomarker study group compared with 
management based on standard care (26·4% of patients 
vs 5·7% of patients; aOR 5·78 [95% CI 1·27–26·23]; 
p=0·023; figure 2C; table 4). Despite this reduction in 
corticosteroid, symptoms, lung function, and exacer-
bation rates did not change (table 4). There was also no 
difference in lung function, symptom scores, quality of 
life, or biomarker profile in patients who reduced their 
corticosteroid treatment (appendix p 9).
The median corticosteroid dose reduction in those 
patients who reduced their corticosteroid treatment 
in the ITT, PP, and ACQ-7 ≥1·5 analyses was 1000 μg 
beclometasone dipropionate equivalent consistently 
across all analyses (appendix p 9). There was no reduction 
in the median OCS dose in any analysis.
Of the 209 patients at the end of the study who felt they 
could identify which treatment strategy they had been 
assigned, 60 (36%) of 165 patients in the biomarker 
strategy group thought that they had been assigned to the 
control group, despite being told in the study information 
at the outset that they had a four out of five chance of 
being assigned to the biomarker strategy group. In the 
control group, 23 (52%) of 44 patients thought that they 
were receiving biomarker-directed treatment. There was 
no significant difference in whether they correctly 
identified their treatment group, suggesting that the 
strategy employed to mask patients to their treatment 
strategy had been effective.
An important secondary aim of the study was to identify 
how many patients could reduce their corticosteroid dose 
to the lowest dose of ICS and remain composite T2 
biomarker-low. Of the patients recruited to the biomarker 
strategy group who completed the study, only nine (4%) 
of 209 patients successfully withdrew their corticosteroid 
treatment so that they achieved the lowest dose of ICS 
and remained biomarker-low (ie, a composite score 
of zero). Two other patients received serial advisories to 
reduce their corticosteroid dose because they were 
biomarker-low, but they did not successfully reduce to the 
lowest ICS dose. Taken together, 11 (5%) of 209 patients 
were composite biomarker-low.
There was no difference in mild or moderate 
adverse events between study groups (rate ratio 
[symptom:biomarker] 1·10, 95% CI 0·96–1·26) and 
there was no difference in severe adverse events between 
study groups (rate ratio [symptom:biomarker] 1·26, 
95% CI 0·78–2·05). There was an increased rate of 
reported serious adverse events in the control group 
compared with the biomarker strategy group (rate ratio 
[symptom:biomarker] 1·64, 95% CI 1·04–2·60). There 
was no difference between study groups in the adjusted 
rate of hospitalisations for asthma (table 4).
Discussion
This study compared T2 biomarker-directed corticosteroid 
treatment with a standardised clinical strategy based on 
current symptoms and recent exacerbation history in 
people with severe asthma treated with high-dose ICS. We 
found no significant difference between these strategies 
in the proportion of patients able to lower the dose of their 
corticosteroids in the ITT study population. The aim of 
the study was to reduce corticosteroid dose in a population 
of T2-biomarker-low patients and importantly, in terms of 
effect on the patients, there was no evidence of worsening 
of asthma control or changes in T2-associated biomarkers 
in those patients who reduced their dose.
Figure 3: Proportion of patients who did or did not follow treatment advisories and had a severe asthma 
exacerbation
(A) In the biomarker strategy group. (B) In the control group. 















































Did not follow treatment advisories
Adjusted hazard ratio 1·64 (95% CI 1·13–2·38); p=0·010















































Adjusted hazard ratio 1·07 (95% CI 0·64–1·79); p=0·80
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In contrast to the findings in the ITT population, the 
prespecified PP analysis showed a significantly greater 
proportion of patients reducing their corticosteroid 
treatment in the biomarker strategy group compared 
with the control group. The larger effect size seen in the 
PP analysis was principally because fewer patients 
reduced corticosteroid treatment in the control group, 
which might in part have been due to patients being 
more symptomatic compared with the ITT control 
population. The predominant reason for the low number 
of patients in the PP control group was that patients 
chose not to follow treatment advisories, including (in 
some situations) patients not increasing treatment after 
loss of asthma control. In both treatment groups, as 
expected, patients were reluctant to initiate regular OCS, 
but the reluctance to reduce ICS treatment was not 
expected, particularly since this intention had been 
communicated to patients as a core aim of the study 
before recruitment. We noted that biomarker-low 
patients in the biomarker strategy group who were more 
symptomatic and had lower lung function were less 
likely to agree to reduce their corticosteroid treatment. 
This finding suggests that some of these patients might 
have benefited from a more thorough explanation of the 
dissociation between their symptoms and corticosteroid 
dose when T2 biomarkers are low, which might have 
assisted them in agreeing to corticosteroid reduction.
There was a broad difference between clinical centres 
in the proportion of participants adhering to the protocol 
and specifically those following treatment advisories. 
The reason for this is unclear and will require further 
research. Treatment reductions seen in the PP analysis 
mirrored the assumptions in our power calculations 
estimating the potential benefit of a biomarker-based 
approach.
Given that participants who chose not to reduce 
corticosteroid treatment in the biomarker strategy group 
were more symptomatic, we did a post-hoc analysis to 
explore the effects of biomarker-based management in 
patients with uncontrolled asthma (ACQ-7 ≥1·5). These 
findings were in line with our PP analysis, where a 
biomarker-directed approach to treatment resulted in a 
significant proportion of these symptomatic patients 
being able to reduce their corticosteroid treatment 
with no evidence of worsening in control of their asthma. 
As some biomarker-low patients with high symptom 
scores were reluctant to reduce treatment, we believe 
the scale of the benefit, in terms of the proportion 
who could reduce treatment, might have been under-
estimated in this analysis. As there were fewer 
opportunities for symptom-based treatment reduction in 
this sub-population, they serve as a useful treatment-
stable comparator group, showing little difference in 
clinical outcomes in the biomarker strategy group 
who reduced their treatment significantly compared 
with the control group who did not. The uncontrolled 
asthma analysis is particularly relevant since it describes 
a common clinical problem: a highly symptomatic patient 
potentially overtreated with corticosteroids. By means of 
an asthma guideline-based approach to treatment, this 
group could often see their corticosteroid dose increased 
owing to high symptom burden, but this analysis suggests 
that a biomarker-based strategy in this group might 
successfully and substantially reduce corticosteroid 
treatment with no deterioration in asthma control or lung 
function or increased exacerbation of T2 inflammation 
based on biomarker profile.
This study had a high retention of patients, including 
those who did not follow treatment advisories, allowing 
the opportunity to compare the risk of severe exacerbation 
in participants who did and did not follow treatment 
advice in either study group. However, given the 
pragmatic nature of the study, we did not track patient 
adherence to treatment advisories in real time (ie, 
treatment adjustment was reviewed at next study visit) 
and it was not possible to monitor differences in the 
proportion of patients not following advisories at the 
different sites. Increased risk of exacerbation in patients 
with severe asthma who were biomarker-high was not 
unexpected but the increased risk observed in biomarker-
low patients who did not reduce their corticosteroid dose 
was not expected. The use of both OCS and ICS has been 
associated with increased risk of infections and azithro-
mycin has been shown to reduce severe exacerbations in 
both eosinophilic and non-eosinophilic patients.6,7,17 The 
NOVEL-START study showed a tendency to increased 
severe exacerbations in patients with mild asthma and 
low blood eosinophil counts (<150 cells per µL) initiating 
regular ICS treatment compared with treatment with 
as-needed salbutamol.18 Taken together, these data 
suggest that ICS in doses that suppress substantially 
T2 biomarkers might be harmful in some patients. If so, 
this makes the ability to carefully and safely titrate 
corticosteroid dose to T2-associated biomarker activity all 
the more important. However, given the difficulty that 
some symptomatic patients had in this study to reduce 
treatment when established on high-dose treatment, it 
might be better to use biomarkers to identify the right 
patient before increasing corticosteroid treatment.
The median daily ICS reduction in patients who 
reduced treatment was consistent across all analyses at a 
beclometasone dipropionate equivalent dose of 1000 μg. 
Our expert Delphi consensus advised that at least a 
250–500 μg reduction in daily ICS treatment would be 
regarded as a clinically meaningful dose reduction in a 
severe asthma population on high-dose ICS, suggesting 
that severe asthma specialists will recognise this as a 
substantial treatment benefit.15
The current study also aimed to establish the 
prevalence of T2 biomarker-low asthma in our severe 
asthma population when the corticosteroid dose was 
reduced to a minimum, because it is recognised that 
exposure to corticosteroids downregulates T2 biomarkers 
and overtreatment might potentially overestimate the 
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prevalence of the T2 low phenotype.19 At study entry, 
23% of participants were composite biomarker-low, 
which was in line with our analysis of the placebo groups 
of clinical trials with lebrikizumab and omalizumab 
(appendix p 6).13 However, only 11 (5%) of 209 patients 
managed either to down-titrate successfully to the lowest 
dose of ICS and remained biomarker-low or remained 
serially biomarker-low and did not reduce their 
corticosteroid treatment. These data suggest that ICS 
can be reduced cautiously to relatively low maintenance 
levels in T2 biomarker-low patients, and this would 
seem important before assigning any phenotypic label. 
It further implies that T2 biomarker-low severe asthma, 
as defined in this study, is uncommon. We propose that 
detailed clinical assessment including corticosteroid 
withdrawal is important before investigational research 
studies and testing of clinical interventions in this 
T2 biomarker-low population.20
In summary, this study did not meet its primary 
outcome of showing a greater proportion of patients on a 
lower corticosteroid dose by means of a biomarker-based 
strategy in severe asthma compared with corticosteroid 
adjustment based on symptoms and previous exacerbation 
history in the ITT population. We noted a large number of 
patients who did not follow treatment advisories to reduce 
corticosteroid treatment in both treatment groups; 
understanding the reasons for this finding is an important 
area for future research. In the study population who 
followed treatment advice per protocol or who had 
uncontrolled asthma at study entry, meaningful cortico-
steroid reduction was achieved. A biomarker-adjusted 
corticosteroid strategy seems particularly beneficial in 
those patients where symptoms and T2 biomarker profile 
are discordant and, as seen in up to 50% of patients with 
severe asthma;8 we suggest that before progression to 
high-dose inhaled and systemic corticosteroid treatment, 
predictive biomarkers of therapeutic response should be 
assessed. Once established on this dose, biomarker-driven 
dose reduction can be particularly challenging in patients 
with high levels of asthma symptoms.
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